KBP Biosciences

Novo Nordisk, chronic kidney disease, Kerendia, non-steroidal mineralocorticoid receptor antagonist, product acquisition, KBP Biosciences

Novo Nordisk acquires Corvidia Therapeutics for $1.3B to compete with Bayer’s Kerendia

Anika Sharma

Novo Nordisk, riding high on the success of its semaglutide sales, has taken a strategic leap by investing up to ...